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Objective: The goal of the current investigation was to explore whether salivary DJ-1
could be a potential biomarker for monitoring disease progression in Parkinson’s disease
(PD) by evaluating the association between salivary DJ-1 concentrations and nigrostriatal
dopaminergic function.
Methods: First, in 74 patients with PD and 12 age-matched normal controls, single photon
emission computed tomography (SPECT) imaging with labeled dopamine transporters
(DAT) (99mTc-TRODAT-1), which has been used for measuring DAT density in PD was
prformed. Then, the DJ-1 level in their saliva was analyzed by quantitative and sensitive
Luminex assay and compared to caudate or putamen DAT density. Finally, based on the
above, our cross-section study was carried out in 376 research volunteers (285 patients
with PD and 91 healthy controls) to measure salivary DJ-1 level.
Results: From our analysis, we found a correlation between salivary concentration of DJ-1
and putamen nucleus uptake of 99mTc-TRODAT-1 in the PD group. Although salivary DJ-1
levels were not affected by UPDRS scores, gender, age, and pharmacotherapy, DJ-1 levels
in H&Y 4 stage of PD were higher than those in H&Y 1-3 stage as well as those in healthy
controls. Salivary DJ-1 also decreased significantly in mixed type PD patients compared to
the tremor-dominant type (TDT) and akinetic-rigid dominant type (ARDT) PD patients.
Conclusions: According to the investigation in a large cohort, we reported for the first
time the prognostic potential of the salivary DJ-1 as a biomarker for evaluating nigrostriatal
dopaminergic function in PD.
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INTRODUCTION
Parkinson disease (PD), the second most common neurodegen-
erative disorder, affects approximately 1.6% of the population
over the age of 65 (Wright Willis et al., 2010). About 70% of
dopaminergic (DA) neurons in the substantia nigra are lost prior
to the development of the characteristic motor symptoms of PD
(Sherer, 2011). Consequently, an early diagnosis of PD is difficult,
by virtue of the dependence upon clinical features. Therefore, the
identification of useful biomarkers to make an early diagnosis,
or for monitoring progression, of PD is needed (Jankovic, 2008;
Haas et al., 2012).
Abbreviations: PD, Parkinson’s disease; CSF, Cerebrospinal Fluids; UPDRS,
Unified Parkinson’s Disease Rating Scale; MMSE, The mini–mental state exam-
ination; HAMD-17, The 17-item Hamilton Rating Scale for Depression; NMS,
Non-Motor Symptom; TDT, Tremor Dominant Type; ARDT, Akinetic-Rigid
Dominant Type; MT, Mixed Type; ST, Striatum; CB, Cerebellum; BPND, Non-
displaceable radioligand; DAT, Dopamine transporters; SPECT, Single photon
emission computed tomography; PET, Positron emission tomography; EDC,
1-Ethyl-3-[3-dimethylaminopropyl; Sulfo-NHS, N-hydroxysulfosuccinimide; MP,
Methylphenidate.
Positron emission tomography (PET) and single photon emis-
sion computed tomography (SPECT) with radiotracer imaging in
the presynaptic nigrostriatal dopaminergic system has enabled the
study of nigrostriatal dopaminergic degeneration in PD patients,
a technique with excellent reproducibility for improving clinical
diagnosis, monitor disease progression, and evaluate the efficacy
of putative neuroprotective therapies (Marek et al., 2001; Stoessl,
2012). 99mTc-TRODAT-1, developed by Kung et al. (1997), has
high affinity and selectivity for Dopamine transporters (DAT),
which are located in dopaminergic nerve terminals and mediate
dopamine reuptake. In addition to its clinical advantages, such as
stability and low toxicity, 99mTc-TRODAT-1 SPECT imaging has
excellent test/retest reproducibility for longitudinal evaluation of
nigrostriatal dopaminergic function in PD patients (Hwang et al.,
2004).
In recent years, a number of biochemical molecules, such as α-
synuclein, DJ-1, tau, etc., in cerebrospinal fluid (CSF) and blood
have been studied as potential biomarkers of PD (Hong et al.,
2010; Waragai et al., 2010), (Mollenhauer et al., 2006; Waragai
et al., 2007). It has been reported that CSF DJ-1 levels in the early
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stage of PD were significantly higher than those in the advanced
stage of PD and non-PD controls (Waragai et al., 2006). However,
another study that included a larger cohort of subjects demon-
strated that CSF DJ-1 levels were decreased in PD patients vs.
controls (Hong et al., 2010). Moreover, it has also been shown
that plasma DJ-1 levels in PD patients were higher than those in
control patients (Waragai et al., 2007), although another study
did not find a difference between PD and control patients (Maita
et al., 2008). These conflicting results are likely due to the limited
numbers of patients, lacking of an efficient detection method, or
biofluid contamination.
Our collaborators have demonstrated that DJ-1 was present
in human saliva in both PD patients and normal controls (NC)
(Devic et al., 2011). However, there was no significant differ-
ence between the two groups. It is still not clear whether salivary
DJ-1 could be a useful indicator to monitor the progression of
PD. In the present study, we measured salivary levels of DJ-1,
followed by analyzing its correlation with DAT, quantified by
99mTc-TRODAT-1 SPECT. Secondly, this study analyzed a large
cohort of subjects to further investigate salivary DJ-1 as a poten-
tial biomarker of PD.
MATERIALS AND METHODS
PARTICIPANTS
This study was approved by the Ethics Committee of Ruijin
Hospital affiliated to Shanghai Jiaotong University School of
Medicine. All subjects provided their written informed consent
for the participation in the study and underwent a thorough
evaluation by obtaining a medical history, physical history, lab-
oratory tests, neurological examinations, and neuropsycholog-
ical assessments performed by multiple rating scales, includ-
ing UPDRS (Unified Parkinson’s Disease Rating Scale), MMSE
(the mini–mental state examination), the HAMD-17 (17-item
Hamilton Rating Scale for Depression), SCOPA-AUT and REM
Sleep Behavior Disorder scales. In addition, UPDRS motor scores
were assessed when patients were in the “on” state. The diagnosis
of PD patients was made by at least two senior movement disor-
der specialists in accordance with the UK PD Society Brain Bank
Clinical Diagnostic Criteria of PD (Hughes et al., 1992). Recruited
control subjects were from the Shanghai Wuliqiao community
and were matched for age and sex with the former two disease
groups, who had no history or any signs or symptoms suggesting
Parkinson-plus syndrome, cognitive impairment, or other neu-
rological diseases. Exclusion criteria included moderate or heavy
cigarette smoking (more than 10 packs/year), alcohol use, and any
psychotherapeutic drug use.
EXPERIMENTAL PROCEDURES
Saliva sample collection and preparation
All saliva samples were collected as described previously with
minor modifications based on the suggestion from our collab-
orator, Professor Jing Zhang at the University of Washington in
Seattle, WA, USA (Devic et al., 2011). All collection procedures
were performed between 9:00 and 11:00 am to avoid any poten-
tial confounding effects of circadian rhythm. The subjects were
fasted 60min prior to sample collection. Five minutes before the
collection, each subject rinsed his mouths with water for 3min
to remove any excess tissue or debris. The subject was told to
tilt his head forward to accumulate his saliva in the mouth and
each sample was collected in a 15ml pre-chilled vial and kept in
the ice before further processing. Saliva samples were collected
in a resting and unstimulated state (i.e., no food, chewing gum,
etc.). When extracting the protein, Protease Inhibitor Cocktail
(100μl/1ml of whole saliva, Cat# P2714, SigmaAldrich, St. Louis,
MO, USA) was added to the sample to minimize protein degra-
dation, and the sample was vortexed repeatedly followed by two
centrifugations. The initial centrifugation was at a low rate of
2600× g for 15min at 4◦C. The precipitate was preserved and
stored at −80◦C. The supernatant was subject to a second cen-
trifugation at a high rate of 15,000× g for 15min at 4◦C. Again,
the precipitate was preserved and stored at −80◦C and the super-
natant was then divided into 0.5ml aliquots and stored at −80◦C
before analysis. The total salivary protein concentration was mea-
sured using a bicinchoninic acid (BCA) protein assay kit (Pierce,
Rockford, IL, USA).
Luminex assay
Coupling of primary antibody to magnetic COOH beads.
Magnetic COOH beads (Cat# MC10052-01, Bio-Rad, USA) were
chemically coupled with a rabbit polyclonal PARK7 (DJ-1) anti-
body (Cat# Ab18257, Abcam, USA) with the amine coupling
kit (Cat# 171-406001, Bio-Rad, USA) according to the manufac-
ture’s protocol (Figure S1). Briefly, 100μl beads were activated
with 10μl EDC (1-ethyl-3-[3-dimethylaminopropyl], 50mg/ml)
and Sulfo-NHS (N-hydroxysulfosuccinimide, 50mg/ml) in the
ProteOn™ Amine Coupling Kit (Cat# 1762410, Bio-Rad, USA).
Ten to Twenty μg of primary antibodies were added to the
activated beads and incubated for 2 h. The coupled beads were
re-suspended in 150μl of storage buffer or an alternate storage
buffer to complement the protein assay. Determination of the
bead concentration was performed using a Coulter Z2 counter or
a hemocytometer to validate the efficiency of the coupling reac-
tion. The coupled beads were then stored at 4◦C and covered with
aluminum foil.
Magnetic bead-based luminex assay. Salivary DJ-1 levels were
measured using established Luminex assays as described previ-
ously, with minor modifications (Devic et al., 2011) Briefly, 50μl
of capture antibody-coupled beads (about 2500 beads per well)
were added to 96 well Bio-Plex Pro Flat Bottom Plates (Cat#
171025001, Bio-Rad, USA) and washed twice using the reagent
kit (Cat# 171304071, Bio-Rad, USA). Then, 50μl diluent recom-
binant human DJ-1 (Covance, USA) were used as standards, and
saliva samples, diluted in equal sample dilution, were loaded on
the magnetic plate with incubation for 2 h at 1000 rpm on a
plate shaker at room temperature in the dark, followed by wash-
ing the plate three times in succession. Subsequently, detecting
antibodies (0.1μg/ml, biotinylated anti-human DJ-1 antibody,
Cat#BAF3995, R&D systems, USA) were added at 50μl per well
on a rotator at room temperature for 60min followed by washing
three times, and the streptavidin-PE was diluted with assay buffer
in the reagent kit for 30min. The plate was then washed three
times and each well received 125μl assay buffer, followed by shak-
ing for 3min and then read via Liquichip Luminex 200TM. The
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concentration of samples was calculated by comparison to a best-
fit standard curve using a sigmoidal 5-parameter logistic equation
(Figures S1, S2). The salivary DJ-1 signal-to-background ratio
was 64. The recovery rate was close to 81% and coefficient of vari-
ation (CV) in duplicate was less than 20%. Finally, the Luminex
assay demonstrated low day-to-day as well as plate-to-plate sig-
nal variability (<10%), with high signal reproducibility (Figures
S3, S4).
SPECT imaging
All subjects were prohibited from any pharmacotherapy affect-
ing the experimental curative effect observation (particularly
dopamine-specific drugs) within the 48 h prior to receiving
an intravenous injection of 2ml containing 20 mCi of 99mTc-
TRODAT-1 in an antecubital peripheral vein. The binding
to DAT was assessed with SPECT imaging 2 h after injec-
tion. 99mTc-TRODAT-1 was prepared from a pre-formulated
lyophilized kit provided by Jiangsu Nuclear Medicine Institute
(WuXi city, China). Subjects were put on the scanning bed in
the supine position with a head holder to avoid motion artifact.
All images were acquired via a double-headed gamma camera
(Simens, Symbia T16). The energy windowwas 140± 14 keV, and
a matrix of 128 × 128 in circular orbit with step and shoot move-
ments of 64 steps used for each head, with a diameter and degree
of rotation of 30 cm and 360◦, respectively. Acquisition time for
the projection was 30 s, with a zoom of 1.45 and a slice thickness
of 3mm. Each patient also underwent brainMRI (1.5 T, Siemens)
with 3mm cuts at the level of the basal ganglia. The MRI study
was performed to establish a reference for the determination of
regions of interest (ROIs) for the uptake of 99mTc-TRODAT-1
visualized with SPECT.
Imaging analyses
Based on individual MRI images, the (ROIs, 776 ± 33mm2)
were placed over the left and right striatum divided into the
caudate nucleus and putamen. The reference background ROI
(2864 ± 60mm2) was placed on the cerebellum of the same
summed image. Two outcomemeasures were computed. The spe-
cific striatal uptake was measured 2 h after injection and was
calculated for both the left and right striatum as the following:
binding potential of the non-displaceable radioligand (BPND) =
ST-CB/CB, where ST, striatum (caudate and putamen) and CB,
cerebellum, and the results were then averaged.
STATISTICAL ANALYSIS
Statistical analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC) and GraphPad Prism for Windows version
5.0 (GraphPad Software, San Diego, CA, USA). To compare enu-
meration data among groups, chi-square test or Fisher’s exact
test was used. We analyzed the data by t-test or One-Way anal-
ysis of variance (ANOVA) if the data was normally distributed.
Non-parametric Kruskal–Wallis ANOVA was used, followed by a
Mann–Whitney U-test for continuous variables if data was not
normally distributed. Additionally, to determine whether a rela-
tionship among variables was present, we used an analysis of
covariance (ANCOVA) model after rank transformation of the
non-normal data to control for potential contributions secondary
to outliers. The analyses were done with and without adjust-
ment for potential confounding of the baseline variables—i.e.,
age, gender. To determine whether a relationship among variables
was present, we obtained the non-parametric spearman corre-
lation coefficients. All values were expressed as mean ± SD. A
two-tailed p value < 0.05 was defined as a statistically significant
difference.
RESULTS
STRIATAL DOPAMINERGIC FUNCTION AND SALIVARY DJ-1 LEVELS
Although there was no statistically significant difference between
the levels of salivary DJ-1 and UPDRS scores in a previous study
(Devic et al., 2011), the results suggested that there might be a
“floor” effect when using UPDRS motor scores. Consequently,
we adopted 99mTc-TRODAT-1 SPECT, a method that has already
proved its important role in the diagnosis and progression of PD,
to evaluate salivary DJ-1 as novel potential biomarker reflecting
nigrostriatal dopaminergic function. As a pilot study, we recruited
12 healthy controls and 74 PD patients, who were matched for
age and sex in the two groups (Table 1). A non-parametric spear-
man correlation analyses revealed that salivary DJ-1 levels slightly
correlated with putamen nucleus uptake of 99mTc-TRODAT-1
in PD patients (Figure 1A) but not within the caudate nucleus
(Figure 1B). No correlation between salivary DJ-1 and the uptake
of 99mTc-TRODAT-1 in either the caudate nucleus or putamen
in the control group was identified (data not shown), with the
potential confounding variables of sex and age controlled for.
SALIVARY DJ-1 IN HEALTHY CONTROLS AND PATIENTS WITH PD IN
LARGER COHORT
Since the above results demonstrated that salivary DJ-1 correlated
with striatal dopaminergic function, indicating a potential value
in the diagnosis of PD, we sought to confirm this finding in a
larger cohort of patients. To accomplish this, 285 PD patients (171
men, 114 women) were recruited for the study. The demographic
data is listed in Table 2, of which the amount of DJ-1 in different
groups was quantified by Luminex assay. The results demon-
strated that there was no statistically significant difference in DJ-1
levels in the PD group compared to the NC group (Figure 2A),
which was consistent with a previous report (Devic et al., 2011).
Table 1 | Summary of demographics and mean regional caudate
nucleus, putamen 99mTc-TRODAT-1 BPND values in PD patients and
control subjects.
Patients Controls
Age
M:F
Duration (years)
61.8 ± 7.8
50/24
4.36 ± 3.59
55.5 ± 6.11
6/6
UPDRS III 17.63 ± 11.69
Average caudate
Average putamen
0.39 ± 0.21**
0.29 ± 0.20**
1.17 ± 0.40
1.11 ± 0.35
Values are means ± SD, **p < 0.01 vs. controls, a non-parametric Mann–
Whitney U-test for variables was used for comparison. (BPND, Non-displaceable
radioligand; DAT, Dopamine transporters; UPDRS, Unified Parkinson’s Disease
Rating Scale).
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FIGURE 1 | Salivary DJ-1 levels and caudate, putamen uptake of
99mTc-TRODAT-1. The uptake of 99mTc-TRODAT-1 was measured by SPECT
and DJ-1 levels in saliva were measured by Luminex assay in 74 PD
patients. (A) Non-parametric spearman’s correlation analysis revealed that
salivary DJ-1 levels were weakly associated with putamen nucleus uptake
of 99mTc-TRODAT-1 in PD patients (p = 0.20, R = 0.151, p = 0.026,
R = 0.258 when normalized). (B) Statistical analysis revealed that salivary
DJ-1 levels did not correlate with caudate nucleus uptake of
99mTc-TRODAT-1 in PD patients whether normalized (p = 0.72, R = 0.043)
or not (p = 0.73, R = −0.041).
In addition, we evaluated the correlation between DJ-1 levels and
UPDRS scores of 285 PD patients, and found that the correla-
tion was of no statistical significance, even after normalization
(Figure 2B). Since there was no difference in salivary DJ-1 lev-
els between PD and NC, we further evaluated whether or not
gender, age, or therapeutics affected DJ-1 levels. We found no
correlation between gender, age and DJ-1 levels in PD and NC
groups (Figures 2C,D). Furthermore, no correlation was found
between therapeutic use and DJ-1 levels, whether normalized or
not (Figure 2E). The above results indicated that salivary DJ-1
was not affected by gender, age, or pharmacotherapy.
ALTERATION OF SALIVARY DJ-1 IN DIFFERENT STAGES AND CLINICAL
SUBTYPES OF PD
Since salivary DJ-1 did not correlate with UPDRS scores, we
sought to stratify salivary DJ-1 levels by disease stage or clinical
subtype. To determine whether salivary DJ-1 levels were altered
during the course of disease, PD patients were divided into dif-
ferent groups according to Hoehn & Yahr (H&Y) stages. After
adjustment for age and gender, the results revealed that salivary
DJ-1 levels in H&Y-4 stage of PD were higher than those in H&Y
1-3 stage (Figure 3A). Moreover, DJ-1 levels in H&Y-4 stage were
higher than those in healthy controls (Figure 3A). These results
suggested that salivary DJ-1 might be a potential biomarker for
monitoring disease progression.
In addition, previous studies have shown that different sub-
types of PD may have different disease progression (Kumru et al.,
Table 2 | Summary of demographics and salivary DJ-1 levels in a
large cohort.
Patients Control
Number of Cases 285 91
Age (years) 63.34±9.11 61.59± 10.61
M:F 171/114 59/32
UPDRS III 23.8±15.7
Cases of Drug Treatmenta 193:12:30:50
Salivary total protein (mg/ml) 1.55±1.07 1.34± 0.95
DJ-1 (ng/ml) 4.11±5.88 3.86± 5.44
DJ-1 normal (ng/mg) 2.92±4.02 3.66± 5.66
Values are means ± SD. aNumber of patients with Parkinson’s disease who were
treated with carbidopa/levodopa alone or together with other anti-parkinsonism
drugs (Type1) vs. those treated with dopamine agonists but not levodopa
(Type2) vs. those treated with other anti-Parkinson’s disease medications (e.g.,
monoamine oxidase B inhibitors and amantadine) only (Type3) vs. those not
treated with any anti-parkinsonism drugs (no Parkinson’s disease medication)
when the saliva samples were obtained (Type4).
2007). Therefore, we further investigated whether salivary DJ-1
levels were altered in different clinical subtypes of PD, includ-
ing tremor dominant type (TDT), akinetic-rigid dominant type
(ARDT), and mixed type (MT) (Romenets et al., 2012). In our
study, 285 PD patients were divided into the above three subtypes,
according to the criteria developed by Carsten Eggers et al. (2011).
After adjustment for age and gender, we found that salivary DJ-1
decreased significantly in MT patients compared to TDT and
ARDT patients (Figure 3B). However, there was no significant
difference between ARDT patients and other groups.
DISCUSSION
To our knowledge, this study is the first to measure salivary
DJ-1 in a large cohort of PD patients and healthy individuals.
The present investigation has resulted in several major advances.
Firstly, although our results demonstrated that DJ-1 levels in
the saliva were not changed significantly in PD patients com-
pared with NC, salivary DJ-1 levels were weakly associated with
putamen uptake of 99mTc-TRODAT-1 in PD patients. Secondly,
several factors critical to DJ-1 levels in saliva were determined,
including the influence of gender, age, and drug effects. Lastly,
we observed a significant difference in salivary DJ-1 levels in PD
patients based on different disease stages and clinical subtypes.
Saliva is an extraordinary medium in terms of research and
diagnostic possibilities (Zhang et al., 2012). Discovery of salivary
biomarkers offers an easy, inexpensive, safe, and non-invasive
alternative to blood/CSF for the detection of disease. Although
great progress has beenmade in the research on salivary biomark-
ers (Bonne and Wong, 2012), there are limited studies in PD
patients. DJ-1 is detectable in both cellular (pellet) and acellu-
lar (supernatant) components of saliva, and multiple potential
sources may contribute to DJ-1 in saliva. The human sub-
mandibular gland which is linked to the central nervous system,
as the main source of the saliva, has recently been shown to be
involved by synucleinopathy in the early stages of PD. Cheek
epithelium, which forms the majority of the cellular component
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FIGURE 2 | Analysis of salivary DJ-1 in healthy controls and patients with
PD in a large cohort. Salivary DJ-1 levels were measured in 91 individual NC
and 285 PD samples by Luminex assay. (A) Quantitative Luminex analysis of
salivary DJ-1 levels in patients with PD and NC by the non-parametric
Mann-Whitney U-test, before and after controlling for potential contributions
secondary to outliers (e.g., age, sex), and no significant differences were
found (p = 0.72, p = 0.84 when normalized). (B) Salivary DJ-1 correlated with
disease severity as measured by UPDRS motor scores was analyzed by the
non-parametric spearman’s correlation analysis, no statistically significance
was achieved (p = 0.92, R = 0.006; p = 0.44, R = 0.05 when normalized). (C)
Salivary DJ-1 levels did not correlate with gender both in individual Parkinson’s
disease and control group (p = 0.21, p = 0.054 when normalized in PD group,
p = 0.20, p = 0.17 when normalized in the NC group). (D) Salivary DJ-1 levels
did not correlate with age both in individual Parkinson’s disease and control
group (p = 0.32, p = 0.81 when normalized in PD group; p = 0.54, p = 0.49
when normalized in the NC group). (E) There is no significant difference
among the different drug treatment groups (Type1, Type2, Type3, Type4)
even in the same disease stage (data not shown), whether normalized
(p = 0.086) or not (p = 0.25). Data shown are mean ± SD. A two tail
p-value <0.05 was defined as statistically significant.
of saliva, could be another potential sources of salivary DJ-1
(Stewart et al., 2014). Devic’s study has demonstrated that DJ-1
was detectable in human saliva, suggesting that saliva could be a
potentially important diagnostic sample source for PD diagnosis
or monitoring (Devic et al., 2011), (Wang et al., 2011). To further
evaluate the clinical value of salivary DJ-1 for PD diagnosis, we
conducted a large cohort study with a total of 376 individuals.
In a previous study (Devic et al., 2011), DJ-1 levels in saliva
were estimated to be 185.7 ± 339 ng/ml in PD patients and
128 ± 116.4 ng/ml in controls. In contrast, our findings showed
that the concentration of salivary DJ-1 in PD and controls were
4.11 ± 5.87 and 3.86 ± 5.44 ng/ml, respectively. The discrepancy
between the two studies could be due to several major differences
between the two investigations. The different capture antibodies
might detect different species of DJ-1. Also, in the current investi-
gation, amuch larger cohort (91 NC vs. 285 patients with PD) was
studied, thus allowing adequate power to resolve several potential
factors which may significantly affect salivary DJ-1 levels.
In our study, we found a weak correlation between salivary
DJ-1 levels with putamen uptake of 99mTc-TRODAT-1 in 74 PD
patients, which was inconsistent with the previous study, in which
there was no correlation between CSF DJ-1 and PET measures of
striatal DA function in total of 26 LRRK2 mutation carriers (Shi
et al., 2012). The different capture antibodies and patients with
different genotype may contribute to the difference.
In the present study, no relationship between DJ-1 levels and
total UPDRS scores was identified. Nevertheless, we found that
salivary DJ-1 levels in the advanced stage of PD were significantly
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FIGURE 3 | Alteration of salivary DJ-1 in different stages and clinical
subtypes of PD. (A) The PD group was divided into four subgroups
according to the Hoehn & Yahr staging, and statistical analysis of salivary
DJ-1 levels in the different disease stages performed: the DJ-1 levels
increased in H&Y-4 stages of PD compared to the other three groups and
NC groups (H&Y-1 vs. H&Y-4 p = 0.001, H&Y-2 vs. H&Y-4 p = 0.003, H&Y-3
vs. H&Y-4 p = 0.014, NC vs. H&Y-4 p = 0.005, H&Y-1 vs. H&Y-4 p = 0.0002,
H&Y-2 vs. H&Y-4 p = 0.001, H&Y-3 vs. H&Y-4 p = 0.014, NC vs. H&Y-4
p = 0.005 when normalized). (B) PD patients were classified as
tremor-dominant type (TDT), if the tremor score was at least twice the
non-tremor score. The patient was classified as akinetic-rigid dominant type
(ARDT) if the non-tremor score was at least twice the tremor score. The
remaining patients, in whom the tremor and non-tremor scores differed by
less than a factor of 2, were classified as mixed type (MT). From the
analysis, MT patients had lower DJ-1 levels than the TDT group (p = 0.02,
p = 0.054 when normalized) and ARDT group (p = 0.016, p = 0.032 when
normalized) when PD patients were divided into tremor dominant, akinetic,
and mixed subtypes. Data shown are mean ± SD. A two tail p-value < 0.05
was defined as statistically significant.
higher than those in the early stage of PD, which is similar to
plasma DJ-1 results (Waragai et al., 2007). As the disease pro-
gresses, the DJ-1 in saliva and plasma are increased, reflecting the
involved process of increasing oxidative stress in advancing stages
of PD (Winkler-Stuck et al., 2005;Waragai et al., 2007;Wang et al.,
2011).
In this study, we studied potential confounders that might
affect the generation of salivary DJ-1. Age and gender dependence
were analyzed in both PD and control samples. Of note, we found
no association of DJ-1 levels with gender or age, which is incon-
sistant with a recent report that found DJ-1 levels in the CSF
increased significantly as a function of age (Hong et al., 2010).
We also collected information on drug treatment and analyzed
the potential effects of pharmacotherapy on salivary DJ-1 level.
Neither did we find that DJ-1 values in the different groups were
any statistically significant difference. Pharmacotherapy did not
affect salivary DJ-1 levels either. However, it remains unknown
whether the activity of DJ-1 generation is influenced by other fac-
tors. For example, it is important to study the effects of drug dose
on salivary DJ-1 levels, however, similar to the research on CSF
DJ-1 mentioned before, it is rather difficult to obtain accurate
cumulative dosage of drug treatment in an investigation due to
alterations of both the types of medication and the dosage of all
drugs taken over time (Hong et al., 2010).
PD can be classified into different clinical subtypes based on
clinical features and pathogenic mechanisms. The different sub-
types exhibit distinct disease courses, drug therapy responses
and prognosis (Shih et al., 2007; Eggers et al., 2011). For
instance, motor function deteriorates more rapidly in ARDT
than TDT cases (Kumru et al., 2007). The underlying mech-
anisms for the different subtypes are not yet clear. In our
study, DJ-1 levels in saliva in the mixed PD subtype, which
one would expect to be the intermediate subtype between
ARDT and TDT subtypes, decreased significantly compared
to both the TDT and ARDT patients. And the fact that the
smaller number of patients included in TDT groups of PD
may explain the result. In spite of it, our study indicated that
different clinical subtypes might have different mechanisms
for disease progression. This finding may help improve strate-
gic planning of therapy or providing a predictor for disease
prognosis.
In the scope of this study, we have not evaluated the salivary
DJ-1 levels in other parkinsonian disorders whose symptoms may
overlap with sporadic PD clinically, such as ET, PSP, andMSA, etc.
Further studies with disease control for important confounding
factors are necessary to determine whether salivary DJ-1 could
differentiate PD from those related disorders.
In summary, our data indicated that DJ-1 in saliva as a poten-
tial diagnostic biomarker is not for distinguishing PD patients
from healthy controls in a large cohort. Neither was it influenced
by gender, age, and pharmacotherapy. The DJ-1 levels in saliva
were well correlated with the different disease stages, thus could
be useful for evaluating disease progression and different clinical
subtypes of PD.
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